ICON8: Weekly Chemotherapy in Ovarian Cancer | Recruiting
ICON8: Weekly Chemotherapy in Ovari... | Recruiting
ICON8: Weekly Chemotherapy in Ovarian Cancer
ICON8
Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Ovarian Cancer
Unfortunately contact details are not available for this trial.
Primary Contact Details
Recruiting
Recruitment Status
NCT01654146
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
The purpose of this study is to determine if weekly chemotherapy (i.e. giving paclitaxel or carboplatin at a lower dose every week) is more effective than standard chemotherapy (paclitaxel and carboplatin given once every three weeks over 18 weeks) in treating ovarian cancer. The investigators also want to see if weekly chemotherapy causes more or fewer side-effects than standard chemotherapy.
Research Details
  • ICON8 is a three-arm, three stage trial. Patients will be randomised in a 1:1:1 ratio. Patients in arm 1 (control arm) will receive weekly carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles. Patients in arm 2 will receive carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles. Patients in arm 3 will receive dose-fractionated weekly carboplatin and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.

    The trial will have three planned stages. Stage 1 will be conducted to confirm feasibility and safety of protocol treatment in all patients and separately in the Delayed Primary Surgery (DPS) patients. The outcome measure for stage 2 will be 9-month progression-free survival (PFS) rate. The primary outcome measures for stage 3 will be PFS and overall survival and secondary outcomes will be toxicity, Quality of Life and Health Economics. If pre-defined levels of deliverability, at stage 1, or activity, at stage 2, are not met then the research arms will be reconsidered.
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : Carboplatin, Drug : Carboplatin, Drug : Paclitaxel, Drug : Paclitaxel

Study Arm Groups : Arm 1 (Control Arm), Arm 2 (Research arm), Arm 3 (Research arm), Arm 1 (Control Arm), Arm 2 (Research arm), Arm 3 (Research arm)

Intervention Type
See Interventions above
Primary Outcome Measures
    Stage 1: Feasibility assessed as the number of cycles and dose intensity of protocol treatment delivered per patient.; 6 months after the 50th patient has been randomised to each arm and 6 months after the 50th patient with a plan to undergo delayed primary surgery has been randomised to each arm; Stage 1: Safety assessed as the rate of any ≥ grade 3 toxicity experienced per patient.; 6 months after the 50th patient has been randomised to each arm and 6 months after the 50th patient with a plan to undergo delayed primary surgery has been randomised to each arm; Stage 2: Progression Free Survival rate at 9 months after randomisation; 9 months after first 62 patients randomised per arm; Stage 3: Progression Free Survival; PFS expected 1 year after last patient is randomised. OS expected 3 years after last patient is randomised.; Stage 3: Overall Survival; PFS expected 1 year after last patient is randomised. OS expected 3 years after last patient is randomised.
Secondary Outcome Measures
    Stage 3: Toxicity assessed by number of participants with adverse events; Expected 1 year and 3 years after last patient is randomised.; Stage 3: Quality of Life; Expected 1 year and 3 years after last patient is randomised.; Stage 3: Health Economics; Expected 1 year and 3 years after last patient is randomised.
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Female
Age Range
18 Years - N/A
Who Can Participate
Patients
Number of Participants
1485
Participant Inclusion Criteria
    Inclusion Criteria:

    - Females aged 18 years or more

    - Signed informed consent and ability to comply with the protocol

    - Histologically confirmed, with core biopsy from a disease site as minimum requirement (cytology alone is insufficient for diagnosis):

    - Epithelial ovarian carcinoma

    - Primary peritoneal carcinoma of Müllerian histological type

    - Fallopian tube carcinoma

    - FIGO stage IC or above, which may be based on clinical and radiological assessment in patients who have not undergone immediate primary surgery

    - Confirmed high-risk histological subtype for patients with FIGO stage IC/IIA disease, namely:

    - High grade serous carcinoma

    - Clear cell carcinoma

    - Other histological subtype considered poorly differentiated/grade 3

    - ECOG Performance Status (PS) 0-2

    - Life expectancy > 12 weeks

    - Adequate bone marrow function:

    - Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/l

    - Platelets (Plt) ≥ 100 x 109/l

    - Haemoglobin (Hb) ≥ 9g/dl (can be post transfusion)

    - Adequate liver function (within 28 days prior to randomisation):

    - Serum bilirubin (BR) ≤ 1.5 x ULN

    - Serum transaminases ≤ 3 x ULN in the absence of parenchymal liver metastases or ≤ 5 x ULN in the presence of parenchymal liver metastases

    - Adequate renal function as defined by GFR (Glomerular Filtration Rate) ≥ 30ml/min.

    Exclusion Criteria:

    - Non-epithelial ovarian cancer, including malignant mixed Müllerian tumours (carcinosarcomas)

    - Peritoneal cancer that is not of Müllerian origin, including mucinous histology

    - Borderline tumours (tumours of low malignant potential)

    - Prior systemic anti-cancer therapy for ovarian cancer (for example chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy or hormonal therapy)

    - Previous malignancies within 5 years prior to randomisation apart from: adequately treated carcinoma in-situ of the cervix, breast ductal carcinoma in-situ, non-melanomatous skin cancer; or previous/synchronous early-stage endometrial cancer defined as stage IA (FIGO 2009) grade 1 or 2 endometrioid cancers with no lymphovascular space invasion

    - Pre-existing sensory or motor neuropathy grade ≥ 2

    - Evidence of any other disease/metabolic dysfunction that in the opinion of the investigator would put the subject at high-risk of treatment-related complications or prevent compliance with the trial protocol

    - Planned intraperitoneal cytotoxic chemotherapy

    - Any previous radiotherapy to the abdomen or pelvis

    - Sexually active women of childbearing potential not willing to use adequate contraception (e.g. oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the study duration and at least six months afterwards

    - Pregnant or lactating women

    - Treatment with any other investigational agent prior to protocol defined progression

    - Known hypersensitivity to carboplatin, paclitaxel or their excipients (including cremophor)

    - History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory in the case of suspected brain metastases. Spinal MRI is mandatory in the case of suspected spinal cord compression. Patients with brain or meningeal metastases are not eligible
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Aviation House 125 Kingsway
London
WC2B 6NH
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
EudraCT Number
Not available for this trial
Funder(s)
  • Cancer Research UK
Other Study ID Numbers
2010-022209-16
Sponsor(s)
Medical Research Council
Key Dates

Recruitment Start Date

Jun 2011

Recruitment End Date

Jun 2017

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

20 Jun 2012

Date updated in source

26 Jul 2012